MarketWatch
Real-time markets & breaking news
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
By Jaimy Lee
Read original article on MarketWatch
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
This story was originally published on MarketWatch. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on MarketWatch